Des-γ-Carboxy Prothrombin (DCP) as a Potential Autologous Growth Factor for the Development of Hepatocellular Carcinoma

Des-γ-Carboxy Prothrombin (DCP) as a Potential Autologous Growth Factor for the Development of Hepatocellular Carcinoma

Des-γ-carboxy prothrombin (DCP) is a prothrombin precursor produced in hepatocellular carcinoma (HCC). Because of deficiency of vitamin K or γ-glutamyl carboxylase in HCC cells, the 10 glutamic acid (Glu) residues in prothrombin precursor did not completely carboxylate to &#947...

Full description

Bibliographic Details
Main Authors:	Yu-Sheng Zhang, Jia-Hui Chu, Shu-Xiang Cui, Zhi-Yu Song, Xian-Jun Qu
Format:	Article
Language:	English
Published:	Cell Physiol Biochem Press GmbH & Co KG 2014-08-01
Series:	Cellular Physiology and Biochemistry
Subjects:	Autologous growth factor Hepatocellular carcinoma (HCC) Angiogenesis Signaling pathways Des-γ-carboxy prothrombin (DCP) Paracrine factor Stimulation
Online Access:	http://www.karger.com/Article/FullText/366308

Similar Items

Des-Gamma-Carboxy Prothrombin (DCP) Antagonizes the Effects of Gefitinib on Human Hepatocellular Carcinoma Cells
by: Yu-Sheng Zhang, et al.
Published: (2015-01-01)

Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma
by: Shintaro Yamazaki, et al.
Published: (2020-09-01)

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization
by: Lee Yong Kang, et al.
Published: (2013-01-01)

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review
by: Endrit Shahini, et al.
Published: (2023-02-01)

Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma
by: Kelley G. Núñez, et al.
Published: (2021-09-01)

New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram
by: Sun T, et al.
Published: (2021-09-01)

Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients
by: Pan YX, et al.
Published: (2021-06-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
by: Young Eun Chon, et al.
Published: (2023-02-01)

Diagnostic value of combined detection of abnormal prothrombin and other two indicators in AFP-negative primary liver cancer patients
by: XU Hanfeng, et al.
Published: (2023-09-01)

Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma
by: Norikazu Tanabe, et al.
Published: (2023-05-01)

Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria
by: Yusuke Yonemura, et al.
Published: (2020-07-01)

Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study
by: Yongwu Chen, et al.
Published: (2023-07-01)

Wnt1 Positively Regulates CD36 Expression via TCF4 and PPAR-γ in Macrophages
by: Shuai Wang, et al.
Published: (2015-02-01)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
by: Kei Moriya, et al.
Published: (2021-02-01)

The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages
by: Takakazu Nagahara, et al.
Published: (2023-01-01)

The Association between Preeclampsia and Defined Polymorphisms in Prothrombin and Coagulation Factor V Genes
by: Zohreh Salari, et al.
Published: (2016-09-01)

Frequency of Factor V Leiden and Prothrombin Polymorphism in South of Iran
by: Javad Dehbozorgian, et al.
Published: (2009-06-01)

Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation
by: Chih-Chien Yao, et al.
Published: (2023-02-01)

A case of congenital prothrombin deficiency with two concurrent mutations in the prothrombin gene
by: Eman M. Mansory, et al.
Published: (2021-05-01)

Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma
by: Yang Yang, et al.
Published: (2021-11-01)

STANDARDIZATION OF PROTHROMBIN TIME TEST AND EVALUATION OF QUALITY OF PATIENT MANAGEMENT WITH WARFARIN
by: A.H ZARGARZADEH, et al.
Published: (2000-12-01)

Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Through NF-κB/Brg1 and TGF-ß1 Pathways Attenuates Cardiac Remodeling in Pressure-Overloaded Rat Hearts
by: Han-Ping Qi, et al.
Published: (2015-01-01)

Association between DCP levels and kidney stone prevalence in US female adults based on NHANES data
by: Heqian Liu, et al.
Published: (2024-03-01)

Editor’s Pick: Hepatocellular Carcinoma. Part 1: Epidemiology, Risk Factors, Pathogenesis, and Pathology
by: Lior Charach,, et al.
Published: (2017-06-01)

Prothrombin expression in cancer-derived cell lines
by: Dunjić Sofija, et al.
Published: (2019-01-01)

Mechanisms of action of cytoplasmic miRNAs. Part 4. Recruitment of the DCP1-DCP2 decapping complex. Mechanisms of final mRNA degradation
by: A.E. Abaturov, et al.
Published: (2022-09-01)

Gestational complications of the prothrombin G20210A mutation related to prothrombin activity
by: M. G. Nikolaeva, et al.
Published: (2020-07-01)

Binding modes of prothrombin cleavage site sequences to the factor Xa catalytic triad: Insights from atomistic simulations
by: Jiachen Li, et al.
Published: (2022-01-01)

CCR4-NOT2 Promotes the Differentiation and Lipogenesis of 3T3-L1 Adipocytes via Upregulation of PPARγ, CEBPα and Inhibition of P-GSK3α/β and β-Catenin
by: Eun Jung Sohn, et al.
Published: (2015-11-01)

Association of prothrombin, FV Leiden and MTHFR gene polymorphisms in the Montenegrin patients with venous thromboembolism
by: Teofilov Slađana, et al.
Published: (2021-01-01)

Clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age
by: Momot AP, et al.
Published: (2019-08-01)

Association of Factor V Leiden and Prothrombin G20210A Polymorphisms in Women with Recurrent Pregnancy Loss in Isfahan Province, Iran
by: Mohammad Taghi Kardi, et al.
Published: (2018-01-01)

Paracrine endocrinology of cardiac telocytes in culture
by: Hua Li, et al.
Published: (2017-01-01)

Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma
Published: (2022-06-01)

Measuring the in situ California Bearing Ratio of a new constructed forest road using DCP
by: Ehsan Abdi, et al.
Published: (2012-06-01)

The appearance of molecules of prothrombin origin in blood upon development of atherothrombotic and cardioembolic ischemic stroke
by: N. Raksha, et al.
Published: (2016-07-01)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
by: Herm Jan M. Brinkman, et al.
Published: (2022-03-01)

Isoliquiritigenin Inhibits Interferon-γ-Inducible Genes Expression in Hepatocytes through Down-Regulating Activation of JAK1/STAT1, IRF3/MyD88, ERK/MAPK, JNK/MAPK and PI3K/Akt Signaling Pathways
by: Shanshan Wu, et al.
Published: (2015-08-01)

A nonneutralizing antibody as cause of prothrombin deficiency in a patient with follicular lymphoma
by: Cecilia Augustsson, et al.
Published: (2024-01-01)

Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma
by: Sung-Yin Wang, et al.
Published: (2022-08-01)